Clinical development at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
56 organizations at World Vaccine Congress Europe 2026 present work in clinical & preclinical development: 31 suppliers and service providers, 9 vaccine and drug developers, 9 academic bodies and 7 public-health and non-profit bodies. Between them they bring 82 presentations to the program. Most represented: Sanofi (8 on the program), GSK (7 on the program), PATH (5 on the program). 47 of them have their own page in this guide. As of Sep 26, 2026.
All 251 organizations at World Vaccine Congress Europe 2026 →
Format
Top represented
Showing 1–8 of 56 organizations
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
Sanofi Paris, France | |
Global pharmaceutical company with a large vaccines business spanning influenza, pediatric, meningitis and mRNA programs. | Talk Mon Oct 19 11:30 Talk Mon Oct 19 14:45 Talk Mon Oct 19 15:30 Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. Talk Wed Oct 21 13:30 Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
GSK London, United Kingdom | |
Panel Mon Oct 19 12:15 Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. Talk Wed Oct 21 13:15 Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. | |
PATH Seattle, WA | |
Global health non-profit working on vaccine development, delivery and immunization systems in low- and middle-income countries. | Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. Talk Mon Oct 19 16:30 Talk Mon Oct 19 16:45 Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. Infectious disease & AMR Talk Wed Oct 21 12:00 Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. |
European Medicines Agency Amsterdam, Netherlands | |
The European Union's medicines regulator, evaluating and monitoring vaccines and medicines. | Panel Mon Oct 19 12:15 Panel: Chronic Conditions and Off-target Effects of Vaccines Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it. Panel Mon Oct 19 14:15 Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery Why common doubts about needle-free vaccine delivery, such as cost, regulation and patient uptake, may no longer hold up. Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:00 Working Group: Quality Communication for Vaccine Literacy and Uptake Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions. Supply, safety & access Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
CEPI Oslo, Norway | |
Coalition for Epidemic Preparedness Innovations: global partnership funding vaccines against emerging infectious diseases and epidemic threats. | Panel Mon Oct 19 12:15 Talk Tue Oct 20 16:00 Panel: Expanding the Access & Impact of Adjuvants How to get past licensing and approval hurdles so new adjuvants, ingredients that boost a vaccine's immune response, reach more countries. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. Panel Wed Oct 21 16:00 Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems How Europe can shift vaccine funding from crisis-driven spending to long-term plans, using tools like joint purchasing and advance promises to buy. Supply, safety & access |
International Vaccine Institute Seoul, South Korea | |
International non-profit organization developing and delivering vaccines for global health. | Talk Mon Oct 19 14:15 Panel: Preparing for Disease X: Approaches for the Next Spillover How to spot the next unknown disease jumping from animals to people early, and how vaccines could be readied or stockpiled beforehand. Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:15 Panel: The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs Why low- and middle-income countries are becoming vaccine innovators, not just trial sites, and what funding and regional regulatory cooperation they need. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. |
Imperial College London London, United Kingdom | |
Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. Talk Wed Oct 21 14:45 | |
UK Health Security Agency (UKHSA) London, UK | |
UK agency that plans for, prevents and responds to health threats, providing scientific and operational leadership nationally and globally. | Booth Exhibiting at Booth 417 Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. Panel Tue Oct 20 17:10 One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy How tracking disease in people, animals and the environment together can set vaccine priorities for infections that jump from animals, like bird flu. One Health & ecosystems Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. |
Instantly find 20 buyers in clinical & preclinical development
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World Vaccine Congress Europe 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction